ATE392215T1 - Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit - Google Patents

Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit

Info

Publication number
ATE392215T1
ATE392215T1 AT00990365T AT00990365T ATE392215T1 AT E392215 T1 ATE392215 T1 AT E392215T1 AT 00990365 T AT00990365 T AT 00990365T AT 00990365 T AT00990365 T AT 00990365T AT E392215 T1 ATE392215 T1 AT E392215T1
Authority
AT
Austria
Prior art keywords
protein
src
modified
yes
inhibitors
Prior art date
Application number
AT00990365T
Other languages
English (en)
Inventor
David Cheresh
Brian Eliceiri
Robert Paul
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/470,881 external-priority patent/US6685938B1/en
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE392215T1 publication Critical patent/ATE392215T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
AT00990365T 1999-12-22 2000-12-22 Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit ATE392215T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/470,881 US6685938B1 (en) 1998-05-29 1999-12-22 Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US53824800A 2000-03-29 2000-03-29

Publications (1)

Publication Number Publication Date
ATE392215T1 true ATE392215T1 (de) 2008-05-15

Family

ID=27043259

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07020078T ATE553782T1 (de) 1999-12-22 2000-12-22 Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung
AT00990365T ATE392215T1 (de) 1999-12-22 2000-12-22 Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07020078T ATE553782T1 (de) 1999-12-22 2000-12-22 Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung

Country Status (19)

Country Link
EP (2) EP1250155B1 (de)
JP (1) JP2003518077A (de)
KR (1) KR100813818B1 (de)
CN (1) CN1434727A (de)
AT (2) ATE553782T1 (de)
AU (1) AU781444B2 (de)
BR (1) BR0016547A (de)
CA (1) CA2395136A1 (de)
CZ (1) CZ304320B6 (de)
DE (1) DE60038631T2 (de)
DK (2) DK1250155T3 (de)
ES (2) ES2383763T3 (de)
HU (1) HU229628B1 (de)
NO (1) NO20023036L (de)
PL (1) PL356815A1 (de)
PT (2) PT1905457E (de)
RU (1) RU2271216C2 (de)
SK (1) SK287575B6 (de)
WO (1) WO2001045751A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
US7115651B2 (en) 2000-08-25 2006-10-03 Sloan-Kettering Institute For Cancer Research Macrocycles and uses thereof
AU2003220390A1 (en) * 2002-03-18 2003-10-08 Medtronic Ave Inc. Medical devices for delivering anti-proliferative compositions to anatomical sites at risk for restenosis
AU2003281152A1 (en) * 2002-07-12 2004-02-02 Yihai Cao A method for inhibiting vascular permeability and tissue edema
EP1413887A1 (de) * 2002-10-22 2004-04-28 Aventis Pharma S.A. Src Kinase Inhibitoren zur Behandlung von Alzheimer Krankheit
WO2004056386A2 (en) * 2002-12-19 2004-07-08 To-Bbb Holding B.V. Nucleic acids involved in blood-brain barrier control
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
EP2233174B1 (de) * 2004-01-21 2016-07-20 Emory University Zusammensetzungen und Verwendungen von Tyrosinkinase-Inhibitoren zur Behandlung von Pathogeninfektionen
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
EP1965762A1 (de) * 2005-12-23 2008-09-10 Alcon, Inc. Pharmazeutische formulierung zur verabreichung rezeptor-tyrosin-kinase-hemmender verbindungen ins auge
US8404632B2 (en) * 2006-05-22 2013-03-26 The Regents Of The University Of California Compositions and methods for the delivery of nitric oxide
ATE417274T1 (de) * 2006-06-01 2008-12-15 Cellzome Ag Verfahren zur identifizierung von mit zap-70 wechselwirkenden molekülen und zur zap-70- reinigung
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
CN102656153B (zh) * 2009-10-29 2015-02-18 延世大学校产学协力团 新型血管渗漏阻断剂
US8557513B2 (en) * 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes
US10293023B2 (en) 2013-03-15 2019-05-21 Children's Medical Center Corporation Method of altering vascular permeability and uses thereof
CN105311645B (zh) * 2015-01-23 2018-11-30 中国人民解放军第二军医大学 胚胎fyn相关底物efs在防治肠道病毒71型感染中的应用
CN105288654B (zh) * 2015-01-23 2018-11-30 中国人民解放军第二军医大学 蛋白酪氨酸激酶fyn癌基因在防治肠道病毒71型感染中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356167A (en) 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US5092885A (en) 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
DK0617124T3 (da) * 1990-01-26 1999-12-06 Washington Res Found Immunreaktivitet overfor udtrykte aktiverede onkogener til diagnose og behandling af maligne svulster
EP0470569B1 (de) 1990-08-08 1995-11-22 Takeda Chemical Industries, Ltd. Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
CA2289102A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6723694B1 (en) * 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
CN1278724A (zh) * 1997-10-06 2001-01-03 巴斯福股份公司 抑制酪氨酸激酶活性的茚并[1,2－c]吡唑衍生物
ATE506073T1 (de) * 1998-05-29 2011-05-15 Scripps Research Inst Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
AU1908000A (en) * 1998-11-06 2000-05-29 Basf Aktiengesellschaft Inhibition of the formation of vascular hyperpermeability

Also Published As

Publication number Publication date
EP1250155A1 (de) 2002-10-23
DE60038631D1 (de) 2008-05-29
NO20023036L (no) 2002-07-22
PT1905457E (pt) 2012-05-25
HU229628B1 (en) 2014-03-28
RU2002119399A (ru) 2004-02-27
BR0016547A (pt) 2002-10-29
PT1250155E (pt) 2008-06-06
ES2383763T3 (es) 2012-06-26
CA2395136A1 (en) 2001-06-28
KR100813818B1 (ko) 2008-03-17
CN1434727A (zh) 2003-08-06
EP1250155B1 (de) 2008-04-16
PL356815A1 (en) 2004-07-12
ATE553782T1 (de) 2012-05-15
EP1905457B1 (de) 2012-04-18
DK1905457T3 (da) 2012-05-29
DK1250155T3 (da) 2008-08-25
HUP0203957A3 (en) 2005-07-28
SK287575B6 (sk) 2011-03-04
ES2303514T3 (es) 2008-08-16
NO20023036D0 (no) 2002-06-21
JP2003518077A (ja) 2003-06-03
AU781444B2 (en) 2005-05-26
EP1250155A4 (de) 2003-08-20
DE60038631T2 (de) 2009-06-10
EP1905457A1 (de) 2008-04-02
CZ304320B6 (cs) 2014-03-05
KR20020063259A (ko) 2002-08-01
SK8492002A3 (en) 2002-11-06
HUP0203957A2 (hu) 2003-03-28
WO2001045751A1 (en) 2001-06-28
RU2271216C2 (ru) 2006-03-10
AU2740001A (en) 2001-07-03

Similar Documents

Publication Publication Date Title
ATE392215T1 (de) Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit
HUS1700003I1 (hu) Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
ATE469888T1 (de) Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren
DE50213524D1 (de) Kationische sterolderivate, ph-sensitive liposomen diese umfassend und verfahren zur wirkstoffbeladung von liposomen
ATE556059T1 (de) Pyrazolderivate zur behandlung von hiv
WO2002057259A3 (en) Pyrazole compounds useful as protein kinase inhibitors
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
ATE260274T1 (de) Furanonderivate als inhibitoren von cathepsin s
DE69912815D1 (de) Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE297222T1 (de) Zusammensetzungen enthaltend eine niedrige konzentration an peroxide zur behandlung von vaginitis
DE60221275D1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
ATE213944T1 (de) Verwendung von immunomodulatoren
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
NO20006026L (no) Fremgangsmåter og blandinger for modulering av angiogenese ved bruk av tyrosin kinase SRC
WO2001079167A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
DE60311284D1 (de) 4-(3,5-dicyanophenoxy)pyrazol-derivate zur verwendung als reverse transkriptase modulatoren zur behandlung von u.a. hiv
DE50105650D1 (de) Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
DE60203726D1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1250155

Country of ref document: EP